Articles tagged with Hypoglycemia
A study of 267 CKD patients found that 69.3% experienced at least one hazardous event related to their outpatient care, with hypoglycemia and falling/severe dizziness being common complications.
Studies examine how depleted food budgets can increase risk of hypoglycemia among low-income individuals with diabetes. Additionally, researchers find that workers with diabetes are more likely to retire earlier in countries worldwide.
Researchers found that longer duration of diabetes and advancing age are associated with increased rates of diabetes complications, hypoglycemia, cardiovascular complications, and mortality. The study highlights the need for individualized care for older patients with type 2 diabetes.
Cardiovascular complications and hypoglycemia are common nonfatal complications in older adults with diabetes. The study found that patients with diabetes for a longer duration had higher rates of all outcomes, including mortality.
A study published in Psychological Science found that people who are hungry are more inclined to support left-wing welfare policies, challenging the traditional notion of what drives political opinions. The researchers suggest this is due to an ancestral impulse to share resources when food is scarce.
The study found that sensor-augmented pump therapy significantly reduced the rate of severe and moderate hypoglycemia among patients with type 1 diabetes, particularly those with impaired awareness. The technology demonstrated potential to reduce the duration and frequency of significant hypoglycemia.
A recent study found that diabetic patients taking oral fluoroquinolones have a higher risk of severe blood sugar-related problems compared to those taking other antibiotics. The increased risk was low, but clinicians should consider this when treating diabetic patients with fluoroquinolones, especially moxifloxacin.
A new study by Kaiser Permanente and Yale University School of Medicine found that severe hypoglycemia affects many patients with poorly controlled type 2 diabetes. Nearly 11% of respondents experienced severe low blood sugar in the prior year, regardless of their blood sugar control level.
A post-hoc analysis found that patients with Type 2 diabetes and mild renal impairment treated with JANUVIA achieved similar blood sugar reductions as those treated with sulfonylureas, with significantly fewer hypoglycemia events. Patients taking JANUVIA also experienced weight loss, whereas those on sulfonylureas gained weight.
A meta-analysis study found that insulin degludec has a similar or reduced risk of recurrent hypoglycemia compared to insulin glargine. The study, involving nearly 3,400 adults with type 2 diabetes, suggests that insulin degludec may offer benefits in reducing the major side effect of insulin therapy.
Researchers found hospitalization for severe hypoglycemia doubled dementia risk, while dementia patients experienced twice as likely severe hypoglycemic events. Cognitive impairment may lead to poor diabetes management and worse health.
A study of 783 older adults with diabetes found a two-fold increased risk for dementia among those experiencing hypoglycemia events. Clinically significant hypoglycemia was also associated with a greater risk for subsequent severe hypoglycemic events.
Researchers at Yale University have identified a protein MKP-5 as a negative regulator of muscle stem cell function, enhancing muscle regeneration in a mouse model of Duchenne muscular dystrophy. Additionally, studies suggest that lactate supports neuronal function and may protect the brain during hypoglycemia.
Researchers found that recurrent hypoglycemia enhances neuronal uptake of lactate, allowing the brain to retain normal neural activity. This suggests that lactate supports neuronal function and indicates potential benefits of supplementing alternative fuels during hypoglycemia.
A second-phase human clinical trial showed the predictive glucose control system can reduce insulin delivery in advance of hypoglycemia and trigger timely warnings. The system demonstrated promising results, keeping glucose levels at an average of 133 mg/dL for the entire cohort.
Researchers at Boston Children's Hospital used a social networking approach to investigate the magnitude of hypoglycemia and promote healthy behaviors among participants with diabetes. The study showed that engaging patients in research through social media can help augment traditional surveillance methods and lead to meaningful behavi...
A randomized trial shows that the dual-hormone artificial pancreas system improved glucose levels and reduced hypoglycemia compared to conventional pump treatment in patients with Type 1 diabetes. The system delivered insulin and glucagon using continuous glucose sensor readings and an intelligent dosing algorithm.
A new study has found that insulin degludec, a long-lasting insulin, reduces the risk of nighttime low blood sugar in elderly diabetic adults compared to insulin glargine. The meta-analysis of phase 3 clinical trials shows that insulin degludec lowers major side effects like hypoglycemia in these patients.
Researchers found that sitagliptin improves the severity of reactive hypoglycemia by enhancing insulin secretion during meals. This study suggests a novel approach to treating this condition, currently with no medical therapy.
A new study found that an experimental insulin drug, degludec, prevented low blood sugar among diabetic patients more frequently than a popular drug, glargine. Degludec caused 14% fewer low blood sugar incidents overall and 37% less at night compared to glargine.
Researchers at Oregon Health & Science University and Legacy Health have discovered a method to stabilize liquid glucagon, enabling its use in standard diabetes pumps. This breakthrough could lead to future-generation artificial pancreas systems that dispense both insulin and glucagon for optimal glucose control.
In a post-hoc analysis, elderly patients with type 2 diabetes treated with JANUVIA achieved similar blood sugar reductions as those treated with a sulfonylurea. Notably, patients taking JANUVIA experienced significantly less hypoglycemia, with an incidence of 6.2% compared to 28.2% in patients taking a sulfonylurea.
Researchers at the University of Cincinnati have identified apolipoprotein A-IV (apoA-IV) as a promising target for a new diabetes treatment. The study found that apoA-IV improves insulin secretion and reduces blood sugar levels in mice with impaired glucose tolerance.
A study found that automatic suspension of insulin delivery via insulin pumps reduces the severity and duration of hypoglycemia in individuals with type 1 diabetes. The 'low glucose suspend' feature significantly decreases hypoglycemic episodes, reducing the risk of rebound hyperglycemia.
A clinical practice guideline recommends continuous glucose monitoring for type 1 diabetes patients who can use devices daily, while also limiting risks of hypoglycemia. The guideline aims to improve glycemic control and reduce hypoglycemia risk in patients with type 1 and type 2 diabetes.
Researchers at the University of Cambridge have identified a rare genetic alteration responsible for a severe form of hypoglycemia. This discovery offers an explanation for the condition and suggests a potential target for new drugs.
A post-hoc analysis shows that JANUMET (sitagliptin/metformin) achieved better A1C goal attainment compared to metformin alone, particularly in patients with baseline A1C between 7.5 and 9.0 percent. The study found that nearly half of these patients achieved the target A1C level after 18 weeks on JANUMET.
A recent survey conducted by the American College of Endocrinology found that over half of individuals with type 2 diabetes have experienced low blood sugar, often during daily activities. The study highlights the need for increased education on blood sugar management and symptom recognition to prevent serious consequences.
A new ultra-long-acting form of insulin, degludec, has shown improved glucose control when administered just three times a week, compared to daily injections. This reduces the risk of hypoglycaemia and improves patient adherence.
A York University study reveals that type 1 diabetes can affect athletic performance, but it can be managed through proper blood sugar management. The research found that sport skill performance was highest when blood glucose values were in a normal range.
A new artificial pancreas system has been developed to mimic the body's natural glucose control mechanism, using insulin and glucagon hormones. The system was tested in a clinical trial with 11 adults with type 1 diabetes, showing that it can maintain near-normal glucose levels without causing hypoglycemia.
A multicenter study found that patients with mild to moderate hypoglycemia had nearly twice the rate of mortality compared to those without the condition. The study suggests that tolerating hypoglycemia may be undesirable and that continuous glucose monitoring could help avoid it.
Versartis announces preclinical abstracts on its two product candidates VRS-859 and VRS-808, which utilize Amunix's rPEG technology to extend biologics' half-life. The compounds aim to reduce dosing frequency and side effects in type 2 diabetes and prevent nocturnal hypoglycemia in type 1 diabetes.
Researchers from USC's Keck School of Medicine presented new findings on the role of exercise in preventing post-exercise hypoglycemia and ways to modulate pancreatic beta cell mass to prevent type 2 diabetes. The studies aim to improve diabetes treatment guidelines, including medication timing and exercise recommendations.
A study found that continuous glucose monitoring (CGM) devices enable people with excellent blood sugar control to continue managing their diabetes while reducing the frequency of low blood sugar events. CGM devices helped participants spend more time in the target blood sugar range and reduced biochemical hypoglycemia.
A study found that hypoglycemia may account for some portion of excess heart-related deaths in CKD patients. Patients with CKD and diabetes are at highest risk of developing hypoglycemia, which can lead to severe health complications.
A study found that severe hypoglycemic episodes are associated with an increased risk of dementia in older adults with type 2 diabetes. Patients who experienced multiple episodes had a significantly higher risk of developing dementia, with a cumulative effect sizeable.
A new study shows JANUVIA (sitagliptin), a diabetes medicine, effectively lowers blood glucose levels in elderly patients with type 2 diabetes and is not associated with hypoglycemia. The study found that advanced age can contribute to the risk of hypoglycemia, which is why this treatment is beneficial for older patients.
JANUVIA showed longer-term efficacy and safety profile in combination therapy with metformin, improving glycemic control in patients with type 2 diabetes. Additionally, the study demonstrated that JANUVIA provided glycemic control regardless of baseline characteristics.
Researchers at USC have found that norepinephrine transmits a 'low blood sugar' message from the hindbrain to the paraventricular hypothalamus, triggering the release of energy stores to replace missing sugars. This discovery provides new insights into glucose sensing mechanisms in the brain and may hold potential for treating diabetic...
A national Joslin-led study found that maintaining tight blood glucose control in people with type 1 diabetes does not lead to long-term loss of cognitive ability. The study, part of the EDIC study, followed participants for 12 years and showed no adverse effects on cognition.
A study of 108 individuals with a HNF4A mutation found an average increase in birthweight of 790g, with over half of the babies classified as macrosomic. Low blood-sugar levels at birth were also more common in these infants.
A study published in JCI Journals found that glucose reperfusion triggers more extensive neuronal death in hypoglycemic mice than prolonged hypoglycemia itself. Gradual increase of blood glucose levels may be a better approach to treat individuals in hypoglycemic coma, but the findings are subject to further clarification.
A study of patients with type 1 diabetes and healthy individuals found that only one patient with T1DM woke up in response to hypoglycemia, compared to ten healthy control participants. The researchers also discovered that increases in plasma epinephrine concentration preceded polysomnographic signs of wakefulness.
A long-term study of DCCT participants found no cognitive impairment from severe hypoglycemic reactions, supporting the safety of intensive diabetes therapy. Higher A1C readings were associated with a decline in motor speed and psychomotor efficiency, but not other cognitive domains.
A large study found that regular physical activity is associated with better glucose control and lower body mass index in children with type 1 diabetes. The research analyzed data from over 19,000 patients and found that increased physical activity was linked to lower HbA1c levels and improved glycemic control.
Researchers investigate the effects of hypoglycemia on insulin therapy in type 1 diabetes and discover a potential solution using urocortin I. Urocortin I suppresses the counterregulatory response to low blood sugar, impairing glucose-sensing neurons in the brain.
A study found that urocortin I impairs glucose-sensing neurons, leading to prolonged hypoglycemic responses. The regulation of the counterregulatory response is largely determined by CRFR2-mediated suppression and CRFR1-mediated activation in the hypothalamus.
In a study published in the Journal of Clinical Investigation, Columbia University researchers discovered that replacing leptin in lean individuals who lost weight restored fat mass and reversed metabolic changes. The findings suggest that therapeutics targeting the leptin signaling pathway may assist in maintaining reduced body weight...
Three patients underwent gastric bypass surgery and developed severe hypoglycemia, requiring partial or complete pancreas removal. Abnormal insulin-producing islet cell proliferation was found in all cases.
The two-year study found that patients treated with Starlix plus metformin had a 50% lower incidence of hypoglycemia compared to those taking glyburide and metformin. This combination therapy resulted in equally effective glycemic control and sustained reductions in post-meal glucose levels.
Researchers at UCSF discovered that administering pyruvate along with glucose after a diabetic coma can prevent brain damage and subsequent memory and learning impairment. The therapy was shown to be more effective than treatment with glucose alone, with rats experiencing significant cognitive deficits when given only glucose.
A new study found that insulin detemir significantly reduces day-to-day variability in blood glucose levels and nighttime hypoglycemia risk compared to NPH. Insulin detemir also leads to less weight gain in patients with type 1 diabetes.
Researchers discovered that the medial prefrontal cortex is activated during hypoglycemia, indicating a link between cognitive processes and innate physiological responses. This finding provides new understanding of how the brain functions during basic responses like those seen in hypoglycemia.
A study by University of Virginia Health System found that drivers with type-1 diabetes are more likely to be involved in car crashes and experience hypoglycemic episodes. The study revealed that only 20% of type-1 diabetic drivers were at increased risk, emphasizing the need for personalized treatment to mitigate this risk.
The study found that the GlucoWatch Biographer improved diabetes control in children by detecting hypoglycemia more frequently and reducing average HbA1c levels. The device was well-tolerated, with only one subject experiencing a mild skin reaction.
A recent study by Duke University Medical Center researchers found that toddlers and preschool children with Type I diabetes can successfully use insulin pumps with proper supervision. The study involved nine children who were treated with insulin pumps for seven to 19 months, resulting in improved blood glucose control and a significa...
A study by Hopkins researcher Jane McGowan found that hypoglycemia altered the ability of certain neurotransmitter receptors to bind glutamate, a key molecule for normal brain function. The research suggests that hypoglycemia may impact the brain's ability to develop normally, particularly in regards to learning and memory.
The Yale School of Medicine has launched a new center to study hypoglycemia, led by Dr. Robert Sherwin and Dr. Douglas Rothman. Researchers will use various technologies to investigate the causes and solutions for hypoglycemia, aiming to prevent severe episodes.
Researchers found slight memory impairment in children on intensive diabetes therapy, with a three-fold higher rate of severe hypoglycemic incidents compared to conventional therapy. The study suggests potential long-term cognitive consequences related to repeated hypoglycemic episodes.